CDK4/6 inhibitors: A potential therapeutic approach for triple negative breast cancer

Triple negative breast cancer (TNBC) cells lack expression of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor‐2 (HER‐2). Thus, TNBC does not respond to hormone‐based therapy. TNBC is also an aggressive subtype associated with poorer prognoses compar...

Descripción completa

Detalles Bibliográficos
Autores principales: Saleh, Lubaid, Wilson, Caroline, Holen, Ingunn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8706744/
https://www.ncbi.nlm.nih.gov/pubmed/34977868
http://dx.doi.org/10.1002/mco2.97

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8706744/
https://www.ncbi.nlm.nih.gov/pubmed/34977868
http://dx.doi.org/10.1002/mco2.97

Ejemplares similares